ArticleJournal of oncology2022
M2 Tumor Associate Macrophage- (TAM-) Derived lncRNA HISLA Promotes EMT Potential in Bladder Cancer.
Article in Journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Macrophage-derived long non-coding RNAs in cancer: pioneering targets for immune modulation and personalized therapy.Frontiers in immunology · 2026Review
- Decoding the role of exosomes in bladder cancer: focusing on tumor progression and immune microenvironment modulation.Frontiers in oncology · 2026Review
- Insights into spheroid formation: interaction of ovarian cancer cells with macrophage populations in the tumor microenvironment.Journal of translational medicine · 2025Article
- LncRNAs as behind-the-scenes molecules in cancer progression through regulating tumor-associated innate immune system cells.Molecular biology reports · 2025Review
- Immune cell-derived exosomal non-coding RNAs in tumor microenvironment: Biological functions and potential clinical applications.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Converting "cold" to "hot": epigenetics strategies to improve immune therapy effect by regulating tumor-associated immune suppressive cells.Cancer communications (London, England) · 2024Review
- LncRNAs in oncogenic microenvironment: from threat to therapy.Frontiers in cell and developmental biology · 2024Review
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tumor-associated macrophages (TAMs) are M2-like phenotype macrophages which contribute to the tumor progression in tumor microenvironment. The precise mechanisms of TAMs were intricated, and recently, it has been illustrated that TAM-derived exosomal lncRNAs played pivotal roles in the tumor development. In the present study, we investigated the role of TAM-derived exosomal lncRNA HISLA in bladder cancer. Materials and Methods: Effects of TAM exosomes and exosomal lncRNA HISLA on migration and invasion in bladder cells were detected by wound healing assay, transwell assay, and western blot assay. Differential expression of lncRNA HISLA in exosomes derived from M0 or TAMs was examined by qRT-PCR. Western blot assay was used to classify the precise molecular mechanisms. Results: We found that TAM-derived exosomes significantly promote the migration and invasion abilities of bladder cells. Expression of epithelial-mesenchymal transition (EMT) markers was obviously affected by TAM exosome administration. Furthermore, we found that the expression of lncRNA HISLA was specifically elevated in TAM exosomes and TAM exosome-treated bladder cells. Silencing of lncRNA HISLA was found to suppress the processes of migration, invasion, and EMT in bladder cells. In addition, we found that Conclusion: In conclusion, our results investigated the prometastatic role of exosomal lncRNA HISLA derived from TAMs in bladder cancer and suggested TAM-derived HISLA as a promising therapeutic target of bladder cancer.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.